… SIV model, we evaluated the therapeutic efficacy of anti-α 4 β 7 antibody administration in
rhesus macaques … of 50 SIVmac251-infected rhesus macaques that initiated ART during either …

… data from both IgG control and anti-α4β7 antibody treated macaques, … SIV infection with
cART and an anti-α4β7 antibody has led to post-treatment control with viremia levels maintained …

… Indian rhesus macaques (19). After discontinuation of ART at 18 weeks after infection, we
did not observe differences between active and control groups in either plasma SIV RNA …

… viremia in the other three macaques rebounded within a median of … in the macaques treated
with the combination antibody therapy … virologic control by bNAbs in SHIV SF162P3 -infected …

… used SIV model, we evaluated the therapeutic efficacy of antia4b7 antibody administration
… higher peak viral loads after infection and the slower virologic control after ART initiation in …

… virologic control. How and why this happens requires further investigation. We speculate
that Rh-α 4 β 7 changes the immunogenicity of the V2-loop region of the envelope, perhaps by …

… reported that SIV infected macaques treated with a combination of ART and α4β7 mAb
were able to achieve sustained virologic control for >2 years after all therapy was withdrawn (…

… antibody treatments. Unlike the published report, we found no sustained virologic control
by these treatments in vivo. A major focus of HIV therapeutic research is to develop treatments …

… efficacy, we therefore tested a new multiantigen SIV DNA … immunogenicity in SIV-infected
rhesus macaques. Our … mucosal homing factors CCR9 and α4β7 on activated lymphocytes [34,…

… ; blockade of α4β7 with an anti-α4β7 monoclonal antibody (mAb) prior to … SIV viremia in
rhesus macaques (RMs). Interleukin-21 (IL-21) administration in antiretroviral therapy-treated, SIV…